STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more
Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
California's insulin sales landscape is a topic of interest as Novo Nordisk's CEO, Mike Doustdar, suggests investors may undervalue the demand for differentiation among obesity drugs. Novo Nordisk gained a significant lead in the U.S. market with its GLP-1 weight loss injection, Wegovy, but faces competition from Eli Lilly's Zepbound.
The analysts predict this sector could be worth over $100 billion annually by 2030. Meanwhile, some drugmakers are withholding applications for health insurance coverage in Switzerland due to concerns about the potential impact of lower prices on their U.S. business, according to a survey by Interpharma. Approximately one-third of innovative medicines were not submitted for coverage under Switzerland's mandatory health insurance system from January 2025 to June 2026, which could limit patient access to new treatments.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
